Main Menu

Opiant Pharmaceuticals, Inc.

Rigrodsky Law, P.A. is investigating Opiant Pharmaceuticals, Inc. (“Opiant”) regarding possible breaches of fiduciary duties and other violations of law related to Opiant’s agreement to be acquired by Indivior PLC.  Under the terms of the agreement, Opiant’s shareholders will receive $20.00 per share plus up to $8.00 per share in contingent value rights.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 06/15/2024

* Indicates a required field.

Back to Page